Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sun Pharmaceutical Industries Ltd.

www.sunpharma.com

Latest From Sun Pharmaceutical Industries Ltd.

Ranbaxy Brothers Arrested, Downward Spiral Intensifies

The Singh brothers of Ranbaxy have been arrested over allegations of financial fraud and things appear headed further downhill. Daiichi Sankyo is also separately pursuing enforcement of damages against the brothers.

Commercial India

Novartis Eyes Fourth Approval For Cosentyx

As Novartis files Cosentyx for non-radiographic axial spondyloarthritis, it is becoming increasingly clear that psoriasis will not be the blockbuster's revenue growth driver going forward.

Immune Disorders Strategy

Facing Regulatory Heat, Indian Pharma Turns To Quality Solutions

Against a backdrop of US FDA warnings and global regulatory convergence, the Indian pharma industry is looking to build in quality from project inception and foster an unbiased approach to quality across global markets, a conference in Mumbai hears.

 

India Quality

Eisai-Mylan Tango for Second Halaven Brand In India But Eyes On Pricing, Generics

Eisai has struck a deal with Mylan for a second brand of Halaven in India, joining a growing list of foreign firms deploying this approach to expand access to novel therapies in the country amid emerging competition.

India Commercial
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register